- Home
- REFI vs FHTX Comparison
REFI vs FHTX Comparison
Compare REFI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | FHTX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.7M | 173.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REFI | FHTX |
|---|---|---|
| Price | $9.83 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $15.13 | $9.89 |
| AVG Volume (30 Days) | 200.7K | ★ 1.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 18.69% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | $30,909,000.00 |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $7.89 | $15.98 |
| P/E Ratio | $17.47 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.69 | $1.79 |
| 52 Week High | $13.49 | $7.61 |
Technical Indicators
Market Signals| Indicator | REFI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.19 | 12.52 |
| Support Level | $9.69 | N/A |
| Resistance Level | $10.97 | $5.35 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 0.65 | 8.11 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.